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Interleukin-1 receptor antagonist (IL-1ra) is an important anti-inflammatory cytokine that blocks all known actions of IL-1 and markedly
protects against experimentally induced ischemic, excitotoxic, and traumatic brain insults. Cannabinoids (CBs) also exert potent anti-
inflammatory and neuroprotective effects, but the mechanisms of their actions are unknown. Here we tested the hypothesis that the
actions of CBs are mediated by endogenous IL-1ra. We report for the first time that both CB1 and CB2 receptors modulate release of
endogenous IL-1ra from primary cultured glial cells. Activation of CB1 or CB2 receptors increased lipopolysaccharide-induced IL-1ra
release, and specific CB1 or CB2 antagonists blocked lipopolysaccharide-induced production of IL-1ra from glial cells. Comparison of
neuronal cultures from wild-type mice and mice lacking IL-1ra (knock-out) indicates that endogenous IL-1ra is essential for the neuro-
protective effects of CBs against excessive activation of glutamate receptors (excitotoxicity) in response to S-AMPA or NMDA. Similarly,
analysis of mixed glial cultures from IL-1ra knock-out mice indicates that endogenous IL-1ra is required for the CB-induced inhibition of
nitric oxide production in response to bacterial lipopolysaccharide. These data suggest a novel neuroprotective mechanism of action for
CBs in response to inflammatory or excitotoxic insults that is mediated by both CB1 and CB2 receptor-dependent pathways.
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Introduction
Cannabinoids (CBs) exert diverse and potent actions in the brain
(Howlett et al., 2002) and are under clinical evaluation as anti-
inflammatory, neuroprotective, and analgesic agents (Mechou-
lam et al., 2002a,b). However, their mechanisms of action are
primarily unknown. CBs modulate inflammatory and immune
responses (Klein et al., 2000; Pertwee, 2002) and are neuropro-
tective in experimentally induced excitotoxicity (van der Stelt et
al., 2001), ischemic (Nagayama et al., 1999), and traumatic brain
injury in rodents (Panikashvili et al., 2001; Mechoulam et al.,
2002b).
Exogenous and endogenous CBs exert neuroprotective and
anti-inflammatory actions on glia and neurons through
G-protein-coupled receptor-dependent pathways (Howlett et al.,
2002). To date, two CB receptors have been identified: the CB
receptor type 1 (CB1), which is expressed mainly in the brain, and
the CB receptor type 2 (CB2), which is expressed primarily in the
immune system, although recent data suggest that CB2 is present
at low levels within the brain (Howlett et al., 2002), and addi-
tional receptors may exist. The neuroprotective actions of CBs
are thought to be mediated through a variety of mechanisms,
including antioxidative actions (Hampson et al., 1998), inhibi-
tion of NMDA-mediated calcium influx (Mackie and Hille, 1992;
Nadler et al., 1993), and inhibition of glutamate release (Shen and
Thayer, 1998). CBs act on glia and neurons to inhibit the release
of proinflammatory molecules, including interleukin-1 (IL-1),
tumor necrosis factor (TNF) , and nitric oxide (NO) (Molina-
Holgado et al., 1997, 2002; Shohami et al., 1997; Puffenbarger et
al., 2000; Cabral et al., 2001), and enhance the release of the
anti-inflammatory cytokines IL-4, IL-10 (Klein et al., 2000), and
IL-6 (Molina-Holgado et al., 1998). IL-1 has been identified as an
important mediator of diverse forms of experimentally induced
brain damage and is expressed rapidly in response to many forms
of experimental brain injury, initially by microglia and later by
astrocytes (Davies et al., 1999). IL-1 receptor antagonist (IL-1ra)
is a potent endogenous antagonist of all IL-1 actions in the brain
(Dinarello and Thompson, 1991), protecting against ischemic,
excitotoxic, and traumatic brain insults (Allan and Rothwell,
2001). Furthermore, inhibition or deletion of endogenous IL-1ra
Received March 25, 2003; revised May 13, 2003; accepted June 2, 2003.
This work was supported by a Wellcome Trust International Travelling Postdoctoral Fellowship (F.M.-H.), Medical
Research Council (United Kingdom) Recognizing Our Potential Awards Grant G9819368, Comisı´on Interministerial
de Ciencia y Tecnologı´a (Ministerio de Educacio´n y Cultura, Spain), and European Union BioMed-2 Programme
Contract BMH4-CT-97-2942. The IL-1ra knock-out mice were a generous gift from Prof. Yoichiro Iwakura (University
of Tokyo, Tokyo, Japan). The cannabinoid HU-210 was a generous gift from Prof. Raphael Mechoulam (Hebrew
University, Jerusalem, Israel).
Correspondence should be addressed to Nancy J. Rothwell, School of Biological Sciences, 1.124 Stopford Building,
Oxford Road, Manchester, M13 9PT, UK. E-mail: nancy.rothwell@man.ac.uk.
F. Molina-Holgado’s present address: Neurology Unit, Department of Clinical Veterinary Medicine, University of
Cambridge, Cambridge, CB3 OES, UK.
J. D. Moore’s present address: Department of Pathology, University of Cambridge, Cambridge, CB2 1QP, UK.
Copyright © 2003 Society for Neuroscience 0270-6474/03/236470-05$15.00/0
6470 • The Journal of Neuroscience, July 23, 2003 • 23(16):6470 – 6474
enhances ischemic brain injury (Loddick et al., 1997) and in-
creases inflammatory responses (Josephs et al., 2000).
The aim of the present study was to test the hypothesis that the
neuroprotective and anti-inflammatory effects of CBs are medi-
ated by endogenous IL-1ra. Primary glial and neuronal cultures
from C57BL/6 wild-type (WT) or IL-1ra knock-out (KO) mice
(Horai et al., 1998) were exposed to inflammatory [bacterial li-
popolysaccharide (LPS)] or neurotoxic (S-AMPA or NMDA)
stimuli. We show here for the first time that the anti-
inflammatory cytokine IL-1ra is an essential mediator of CB ac-
tions on neurons and glia and that both CB1 and CB2 receptors
modulate the release of IL-1ra from primary cultured glial cells.
Materials and Methods
Reagents. All tissue culture reagents were obtained from Invitrogen (Pais-
ley, UK). The antibody for the astrocytic marker, anti-glial fibrillary
acidic protein (GFAP), was from Sigma-Aldrich (Poole, UK), and anti-
bodies for the microglial marker MAC-1 (macrophage adhesion
molecule-1) and neuronal marker NeuN (neuronal-specific nuclear pro-
tein) were from Serotec (Oxford, UK). The synthetic CB agonist HU-210
was a generous gift from Prof. Raphael Mechoulam (Hebrew University,
Jerusalem, Israel), and CP-55940 was from Tocris Cookson (Avon-
mouth, UK). The cannabinoid antagonists SR-141617A and SR-144528
were a generous gift from Sanofi (Montpellier, France). All other re-
agents were obtained from Sigma-Aldrich unless stated otherwise.
Animals. Wild-type C57BL/6 (WT) mice were obtained from Charles
River (Kent, UK) and IL-1ra-deficient (KO) C57BL/6 mice were ob-
tained from Prof. Yoichiro Iwakura (University of Tokyo, Tokyo, Japan).
Animal care procedures were in accordance with the guidelines set by the
European Council directives (86/609/EEC) and the Home Office, Ani-
mals (Scientific Procedures) Act 1986.
Primary mixed glial cultures. Primary, mixed glial cultures were pre-
pared from whole brains of 1-d-old mice (WT or IL-1ra KO mice) ac-
cording to published protocols (Molina-Holgado et al., 2002) and grown
in T150 flasks for at least 14 d in DMEM supplemented with 10% heat-
inactivated fetal bovine serum, 2 mM glutamine, and antibiotics (100
IU/ml penicillin and 100 g/ml streptomycin solution). The medium
was changed twice per week. On reaching confluence [after 13–14 d in
vitro (DIV)], the cells were trypsinized and cultured (5  10 5 cells per
well) for 2–3 d before experiments. Cultures consisted of 70% astrocytes
and 30% microglia, as determined by staining with antibodies for GFAP
and MAC-1, respectively.
Neuronal cell cultures. Primary cerebrocortical neurons were prepared
as described previously (Moore et al., 2002). Briefly, the cortices were
removed from embryonic (day 18) pups from WT or IL-1ra KO mice,
chopped finely, and passed through three glass-fired pipettes of sequen-
tially smaller bores. Cells were centrifuged (150  g, 5 min) and resus-
pended in 20 ml of plating media (Neurobasal medium with B27 supple-
ment plus antioxidants, 2 mM glutamine, 25 M glutamate, 100 IU/ml
penicillin, and 100 g/ml streptomycin). Viable cells were counted by
trypan blue exclusion and seeded (7.5  10 4 cells/cm 2) onto plates
coated with poly-D-lysine. One-half of the media was replaced after 5 and
11 DIV with maintenance medium (Neurobasal medium with B27 sup-
plement minus antioxidants, 2 mM glutamine, 100 IU/ml penicillin, and
100g/ml streptomycin). After 2 DIV, cytosine arabinoside (20M) was
added to the cultures to eliminate the majority of proliferating non-
neuronal cells. These cultures consisted of98% neurons, as assessed by
NeuN immunoreactivity.
Treatment of cells. Glial cells were treated with bacterial LPS [serotype
0128:B12 (Sigma); 1 g/ml] in DMEM for 24 hr at 37°C, in the presence
or absence of the CB antagonists SR-141716A or SR-144528 (1 M), or
the synthetic CB agonists HU-210 (1 or 10 M) or CP-55940 (0.1 or 1
M). The culture supernatants were then analyzed for IL-1ra or nitrite as
described below.
Neuronal cells were pretreated with HU-210 (1 M) for 1 hr at 37°C
and then exposed to S-AMPA (10 M) or NMDA (20 M) for 24 hr at
37°C, and the amount of cell death was measured as described below.
Release of IL-1ra. Immunoreactive IL-1ra in glial cell culture superna-
tants was assayed using a validated, mouse-specific sandwich ELISA
(Safieh-Garabedian et al., 1995), supplied by Dr. Steven Poole (National
Institute for Biological Standards and Control, London, UK). IL-1ra
standards were assayed in triplicate and samples (100 l) in duplicate.
The assay detection limit for IL-1ra was 19 pg/ml.
Assessment of cell death. Cytotoxicity was measured by the release of
cytosolic lactate dehydrogenase (LDH) by dead and dying cells using the
CytoTox-96 LDH assay (Promega, Southampton, UK) according to the
instructions of the manufacturer. Total LDH release was calculated by
incubating untreated cells with 9% Triton X-100 for 45 min (37°C) to
induce maximal cell lysis. Values for treated cells were then expressed as
a percentage of the total LDH release. Background LDH release induced
by media alone was subtracted from the experimental values.
Assay of nitric oxide synthase activity. NO synthase activity was assessed
by measurement of nitrite (a breakdown product of NO) accumulation.
Aliquots (100 l) of culture supernatants were mixed with 100 l of
Griess reagent, a colorimetric indicator of the presence of nitrite (Green
et al., 1982), and incubated in the dark at room temperature for 10 min.
The absorbance was measured at 570 nm in a microplate reader. Fresh
culture medium served as controls in all experiments.
Statistical analysis. Results are presented as the mean SEM of at least
Figure 1. Modulation of IL-1ra release by LPS and CB antagonists and agonists in primary
mixed glial cultures from C57BL/6 (WT) mice. Mixed glial cultures were treated with medium
(Control) or LPS in the presence or absence of HU-210, CP-55940, SR-141716A, or SR-144528. a,
Effect of LPS and SR-141716A or SR-144528 on IL-1ra release. b, Effect of LPS and HU-210 on
IL-1ra release. c, Effect of LPS and CP-55940 on IL-1ra release. Data are presented as mean
SEM of four independent experiments on separate cultures, each performed in triplicate. Sta-
tistical differences (one-way ANOVA and Newman–Keuls multiple test): *p 0.001 versus
control; #p 0.001 versus LPS.
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three different experiments performed on separate cell preparations, and
duplicate or triplicate determinations were performed in each experi-
ment. To determine differences between groups, one-way ANOVA was
followed by posteriori Newman–Keuls multiple comparison. Statistical
significance was established at p 0.05.
Results
Cannabinoid agonists and antagonists modulate LPS-induced
IL-1ra release from glial cells
Wild-type, primary, mixed glial cultures were used to test
whether LPS-induced IL-1ra release is regulated by CB receptors,
using specific and potent antagonists for the CB1 (SR-141617A)
and CB2 (SR-144528) receptors (Howlett et al., 2002). Basal re-
lease of IL-1ra was not affected by incubation with CB1 or CB2
antagonists alone (data not shown). LPS increased release of IL-
1ra by 15-fold (Fig. 1a), and this was almost completely abolished
by cotreatment with either CB receptor antagonist (SR-141716A
or SR-144528, by12-fold and13.6-fold, respectively). Thus,
CB receptors regulate LPS-induced IL-1ra release. Moreover, the
synthetic CB agonists HU-210 and CP-55940 had no effect on
basal IL-1ra release (data not shown), but they enhanced LPS-
induced IL-1ra release (by 28 and 15%, respectively) in WT
mixed glial cultures (Fig. 1b,c).
Endogenous IL-1ra mediates the neuroprotective actions of
cannabinoids on excitotoxicity in primary neuronal cultures
We next investigated whether endogenous IL-1ra contributes to
the neuroprotective actions of CBs against excessive activation of
glutamate receptors (excitotoxicity), induced by exposure of pri-
mary cerebrocortical neurons from WT and IL-1ra KO mice to
S-AMPA or NMDA. In WT neuronal cells, both glutamatergic
agonists increased cell death significantly (Fig. 2a,b), and the
CB agonist HU-210 significantly inhibited the cell death in-
duced by S-AMPA (38%) or NMDA (51%) (Fig. 2a,b).
S-AMPA and NMDA were also cytotoxic in cells from IL-1ra
KO mice, but the neuroprotective effects of HU-210 were
completely abolished (Fig. 2c,d).
Endogenous IL-1ra mediates the anti-
inflammatory actions of cannabinoids
in glial cells
The contribution of endogenous IL-1ra to
the actions of CBs was further analyzed by
testing the effects of the synthetic cannabi-
noid agonists HU-210 and CP-55940 on
LPS-induced NO synthase activity, be-
cause NO is an important mediator of
neuroinflammation and neurodegenera-
tion (Hobbs et al., 1999). HU-210 or CP-
55940 significantly inhibited the release of
NO induced by LPS in WT glia (55 and
25%, respectively) (Fig. 3a,b). In contrast,
HU-210 and CP-55940 failed to inhibit the
LPS-induced release of NO in mixed glial
cultures from IL-1ra KO mice (Fig. 3c,d).
Similar effects were observed when mixed
glial cultures from KO mice were coincu-
bated with LPS and the synthetic CB meth-
anandamide or 11-OH-CBN (data not
shown).
Discussion
Cannabinoids have potent anti-inflammatory
and neuroprotective effects in the brain,
but the underlying mechanisms are un-
clear. We and others have shown previ-
ously that CBs can modulate production
of inflammatory mediators, including
Figure 2. Neuroprotective effects of HU-210 on excitotoxicity in primary neuronal cultures.
Neuronal cultures from WT (a, b) or IL-1ra KO (c, d) mice were pretreated with HU-210 before
addition of S-AMPA (a, c) or NMDA (b, d). Data are presented as mean SEM of four indepen-
dent experiments on separate cultures, each performed in triplicate. Statistical differences
(one-way ANOVA and Newman–Keuls multiple test): *p  0.001 versus control or HU210
alone; #p 0.001 versus S-AMPA or NMDA.
Figure 3. Modulation of NO release by LPS and CB agonists in primary mixed glial cultures from WT or IL-1ra KO mice. Primary mixed
glial cultures were treated with medium (Control) or LPS in the presence or absence of HU-210 or CP-55940. a, b, Effect of HU-210 or
CP-55940 on LPS-induced NO2
[minus] production in mixed glial cultures from WT mice. c, d, Effect of HU-210 or CP-55940 on LPS-induced
NO2
[minus] productioninmixedglialculturesfromIL-1raKOmice.DataarepresentedasmeanSEMoffour independentexperimentson
separate cultures, each performed in triplicate. Statistical differences (one-way ANOVA and Newman–Keuls multiple test): *p 0.001
versus control; #p 0.001 versus LPS
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the cytokines TNF and IL-6 (Molina-Holgado et al., 1998;
Klein et al., 2000; Puffenbarger et al., 2000) and generation of Th1
and Th2 phenotypes (Yuan et al., 2002). The present report ex-
tends these studies and suggests for the first time that the neuro-
protective and anti-inflammatory effects of CBs are mediated by
CB-induced release of endogenous IL-1ra in primary neurons or
glial cells in vitro. The synthetic CB agonists HU-210 and CP-
55940, which have similar affinities for CB1 and CB2 receptors
(Howlett et al., 2002), increased LPS-induced IL-1ra release from
primary glial cells. Similar results were obtained with other can-
nabinoids, including 11-OH-CBN, and the endogenous canna-
binoid anandamide (data not shown). The potent and specific
antagonists for CB1 and CB2 receptors, SR-141716A and SR-
144528, respectively, significantly abrogated the LPS-induced IL-
1ra release, implicating both CB receptors in this effect. Because
neither the CB agonists nor antagonists altered basal release,
these results indicate that cannabinoids enhance release of IL-1ra
specifically in response to proinflammatory stimuli. The exact
participation of CB1, CB2, or new CB receptors in these neuro-
protective actions remains to be elucidated.
HU-210 and CP-55940 may promote LPS-induced IL-1ra
expression and release directly, or they could modulate IL-1ra
expression via an intermediate, such as IL-6. In support of the
latter hypothesis, it has been reported that neutralization of
endogenous IL-6 suppresses induction of IL-1ra (Jordan et al.,
1995), and CB agonists modulate IL-6 production in glial cells
by a CB receptor-mediated pathway (Molina-Holgado et al.,
1998).
CBs are neuroprotective in a variety of in vitro and in vivo
models of neuronal excitotoxicity. In the present study, low doses
of HU-210 reduced cell death of WT neurons in response to
S-AMPA or NMDA receptor activation. In contrast, HU-210
failed to protect against S-AMPA- or NMDA-induced death of
neurons from IL-1ra KO mice. These results are consistent with
previous observations that endogenous IL-1ra is neuroprotective
(Loddick et al., 1997) and suggest that CB-induced neuroprotec-
tion is mediated, at least in part, by endogenous IL-1ra.
Many cell types are susceptible to excessive NO generation,
and reduction of NO production markedly improves cell survival
and is potentially beneficial in the treatment of a range of pathol-
ogies, including septic shock, neurodegeneration, and inflamma-
tion (Hobbs et al., 1999). CBs inhibit generation of NO by glial
cells (Cabral et al., 2001; Molina-Holgado et al., 2002), and the
present results demonstrate that reduction of LPS-induced NO
generation by CBs in glial cells is dependent on endogenous
IL-1ra.
In summary, the results presented here support our hypothe-
sis that endogenous IL-1ra mediates the neuroprotective and
anti-inflammatory actions of CBs in primary neurons and glia.
These effects appear to be mediated by both CB1 and CB2 recep-
tors. CB-induced IL-1ra release may negatively regulate IL-1
actions in the brain, via IL-1ra blocking the IL-1 receptor (IL-
1RI), after inflammatory or excitotoxic insults. It is tempting to
speculate therefore that the neuroprotective and anti-
inflammatory actions of CBs depend in part on modification of
the balance between proinflammatory and anti-inflammatory
cytokines. These findings have important implications for our
understanding of the mechanisms of action of CBs in diverse
CNS disorders and for the development of new neuroprotective
therapies.
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